Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
  • A61K31/4164—1,3-Diazoles
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
  • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
  • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
  • A61K31/4164—1,3-Diazoles
  • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
  • A61K31/4164—1,3-Diazoles
  • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
  • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
  • A61K38/22—Hormones
  • A61K38/31—Somatostatins
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P5/00—Drugs for disorders of the endocrine system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P5/00—Drugs for disorders of the endocrine system
  • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P5/00—Drugs for disorders of the endocrine system
  • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
  • A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P5/00—Drugs for disorders of the endocrine system
  • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P5/00—Drugs for disorders of the endocrine system
  • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
  • A61P5/12—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P5/00—Drugs for disorders of the endocrine system
  • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
  • A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids

Definitions

• the present invention relates to a combination which comprises (a) a somatostatin analogue and (b) a 1 lbeta-hydroxylase inhibitor; each in free form or in the form of a pharmaceutical acceptable salt thereof; the use of such a combination for the preparation of a medicament for the treatment of diseases associated with increased stress hormone levels; a commercial package or product comprising such a combination; and to a method of treatment of a warm-blooded animal, especially a human.
• Pasireotide is called cyclo[ ⁇ 4-(NH 2 -C 2 H 4 -NH-CO-0-)Pro ⁇ -Phg-DTrp-Lys-Tyr(4-Bzl)- Phe], wherein Phg means -HN-CH(C 6 H5)-CO- and Bzl means benzyl, in free form, in salt or complex form or in protected form.
• Cushing's syndrome is a hormone disorder caused by high levels of Cortisol in the blood. This can be caused by taking glucocorticoid drugs, or by tumors that produce Cortisol or adrenocorticotropic hormone (ACTH) or CRH.
• Cushing's disease refers to one specific cause of the syndrome: a tumor (adenoma) in the pituitary gland that produces large amounts of ACTH, which elevates Cortisol. It is the most common cause of Cushing's syndrome, responsible for 70% of cases excluding glucocorticoid related cases.
• the significant decrease of Cortisol levels in Cushing's disease patients on pasireotide support its potential use as a targeted treatment for Cushing's disease (Colao et al. N Engl J Med 2012;366:32 ⁇ 12).
• Compound A can be synthesized or produced and characterized by methods as described in WO2007/024945. SUMMARY OF INVENTION:
• the somatostatin analogue is octreotide, vapreotide, lanreotide, or pasireotide.
• the somatostatin analogue is pasireotide or any of its pharmaceutically acceptable salts.
• Preferred salts are the lactate, aspartate, benzoate, succinate and pamoate including mono- and di-salts, more preferably the aspartate di-salt and the pamoate monosalt.
• Certain salts of pasireotide forms gel in a aqueous enviroment, such as salt of aspartate, e.g. mono- or diaspartate, glutamate, e.g. mono- or diglutamate, or succinate, e.g. mono- or disuccinate, lactate, acetate or citrate.
• the pasireotide pharmaceutically acceptable salt is pamoate salt.
• the preferred salt of Compound A is phosphate salt or nitrogen salt. More preferably it is the dihydrogenphosphate salt.
• phosphate salt refers to the acid addition salt of compound A with phosphoric acid. More particularly, it refers to the dihydrogenphosphate of compound A protonated once, that is, wherein compound A is protonated once and thus each molecule carries a single positive charge, while the counterion is H 2 PO 4 " ).
• Pharmaceutically acceptable carrier includes any and all solvents, dispersion media, coatings, surfactants, antioxidants, preservatives (e.g., antibacterial agents, antifungal agents), isotonic agents, absorption delaying agents, salts, preservatives, drugs, drug stabilizers, binders, excipients, disintegration agents, lubricants, sweetening agents, flavoring agents, dyes, such like materials and combinations thereof, as would be known to one of ordinary skill in the art.
• preservatives e.g., antibacterial agents, antifungal agents
• isotonic agents e.g., absorption delaying agents, salts, preservatives, drugs, drug stabilizers, binders, excipients, disintegration agents, lubricants, sweetening agents, flavoring agents, dyes, such like materials and combinations thereof, as would be known to one of ordinary skill in the art.
• the time intervals are chosen such that the effect on the treated disease in the combined use of (a) and (b) is larger than the effect which would be obtained by use of only any one of the combination partners (a) and (b).
• the ratio of the total amounts of the combination partner (a) to the combination partner (b) to be administered in the combined preparation can be varied, e.g. in order to cope with the needs of a patient sub-population to be treated or the needs of the single patient which different needs can be due to age, sex, body weight, etc. of the patients.
• there is at least one beneficial effect e.g. a mutual enhancing of the effect of the combination partners (a) and (b), in particular a synergism, e.g. a more than additive effect, additional advantageous effects, less side effects, a combined therapeutic effect in a non-effective dosage of one or both of the combination partners (a) and (b), and very preferably a strong synergism of the
• the present invention provides the Combination of the Invention for use in the treatment of disease states characterised by elevated level of stress hormone.
• stress hormone relates to a hormone which is secreted in response to an unusual exposure to life.
• the stress response involves the activation of both the sympathetic adrenomedu!lary system with the secretion of epinephrine and norepinephrine, and the hypothalamic pituitary adrenocortical (HPA) system with the secretion of Cortisol.
• a stress hormone is aldosterone or Cortisol, preferably Cortisol.
• the term "elevated level of Cortisol” refers to a level higher than 80 ⁇ g /24h, higher than 100 ⁇ g /24h or higher than 120 ⁇ g /24h or higher than 150 ⁇ g/24h.
• Cardiac cachexia is a serious complication of chronic heart failure as patients suffer from a general loss of fat tissue, lean tissue and bone tissue. Cardiac cachexia patients show raised plasma levels of aldosterone and Cortisol as well as reduced levels of
• the present invention provides a use of Compound A in free form, complex form or in the form of a pharmaceutically acceptable salt, for the preparation of a medicament to be used in combination with a somatostatin analogue.
• the present invention provides a commercial package comprising the
• the phosphate salt was soluble at the 0.1% target concentration and stable for 2 days at 50°C.
• the free base remained largely insoluble. It converted from a free flowing solid into an oily material within a short time after contact with water, and remained as such for the 2 day period at 50°C.
• Sorption/desorption isotherms were measured using the VTI 100 humidity microbalance (VTI Corporation, Hialeah, FL, USA). Measurements were carried out at 25°C. Samples were dried under 2 flow at 25°C.
• solubility of the phosphate salt is comparably low in non-aqueous solvents which are thus anti-solvents for the salt, thus making it possible to achieve good precipitation and thus good yields and good purity.
• solubility in water is better than that for the free base which is advantageous for providing oral or parenteral formulations.
• the melting point was determined by TG/DTA as described above and was determined to be 210.2 °C Example 2
• COMPOUND A is a potent inhibitor of 1 1 ⁇ -hydroxylase. Since 11 ⁇ -hydroxylase catalyzes the final step of Cortisol synthesis, COMPOUND A is a potential new treatment for all forms of Cushing's syndrome.
• COMPOUND A formulated in Ultrapure water, was administered by oral gavage (5 mL/kg) alone or in combination to SOM230 , formulated with Acetate buffered solution pH 4.5, for injection USP, and administered by subcutaneous injection (interscapular area, 1 mL/kg) to 5 groups (10/sex/group) of Wistar Hannover rats at daily doses of 1.5/0.03, 5/0.1, 20/0.3, 20/ and /0.3 mg/kg/day COMPOUND A/SOM230.
• Another group of rats (10/sex) received daily doses of Ultrapure water, by oral gavage, and the Acetate buffered solution pH 4.5 for injection USP, by subcutaneous injection, and served as controls.
• animals were approximately 7-8 weeks old and the males were 176 to 216 g and the females were 123 to 165 g.
• COMPOUND A at the maximally tolerated dose with the ability to enter a SOM230 Rescue Phase if needed.
• patients will be assessed to determine entry into one of the two groups for 4 weeks: (1) COMPOUND A b.i.d. plus pasireotide or (2)
• the primary variable is defined as the proportion of responders to
• the proportion of responders and the associated 95% confidence interval will be estimated using the Exact Binomial Test.
• the primary efficacy variable is defined as the proportion of responders to COMPOUND A monotherapy at week 22.
• a patient needing rescue therapy prior to week 22 will also be classified as a non-responder.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Public Health (AREA)
• Chemical & Material Sciences (AREA)
• Veterinary Medicine (AREA)
• Medicinal Chemistry (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Engineering & Computer Science (AREA)
• Endocrinology (AREA)
• Epidemiology (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Organic Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Diabetes (AREA)
• Gastroenterology & Hepatology (AREA)
• Immunology (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Zoology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Priority Applications (12)

Applications Claiming Priority (2)

Publications (1)

Family

ID=48289057

Family Applications (1)

Country Status (13)

Cited By (2)

Families Citing this family (2)

Citations (1)

Family Cites Families (5)

• 2013
  • 2013-04-10 CN CN201380027076.7A patent/CN104321074B/zh active Active
  • 2013-04-10 BR BR112014025058-8A patent/BR112014025058B1/pt not_active IP Right Cessation
  • 2013-04-10 KR KR1020147031324A patent/KR102136214B1/ko not_active Expired - Fee Related
  • 2013-04-10 ES ES13720275T patent/ES2980806T3/es active Active
  • 2013-04-10 MX MX2014012321A patent/MX362533B/es active IP Right Grant
  • 2013-04-10 AU AU2013246908A patent/AU2013246908B2/en not_active Ceased
  • 2013-04-10 IN IN9240DEN2014 patent/IN2014DN09240A/en unknown
  • 2013-04-10 US US14/391,416 patent/US9333234B2/en active Active
  • 2013-04-10 EP EP13720275.0A patent/EP2836228B1/en active Active
  • 2013-04-10 JP JP2015504946A patent/JP6383352B2/ja active Active
  • 2013-04-10 WO PCT/EP2013/057515 patent/WO2013153129A1/en not_active Ceased
  • 2013-04-10 RU RU2014145351A patent/RU2663455C2/ru active
  • 2013-04-10 CA CA2869442A patent/CA2869442C/en active Active

Patent Citations (1)

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events